Gene expression profiling of bovine muscle samples upon experimental treatment with dexamethasone and dexamethasone/Clenbuterol combination
Ontology highlight
ABSTRACT:
ORGANISM(S): Bos taurus
PROVIDER: GSE61934 | GEO | 2015/07/27
SECONDARY ACCESSION(S): PRJNA262699
REPOSITORIES: GEO
Similar Datasets
Project description:In the present study, Bovine transcriptome was characterized in order to identify a set of candidate genes potentially useful for rapid detection of illegal use of some growth promoters (GPs) as dexamethasone (DEX) alone or in combination with the B2-agonist clenbuterol (CLEN). A bovine oligo microarray platform (GPL7053) was used to profile gene expression from twelve (12) bovine biceps brachii samples. Isolated and purified total RNAs were individually hybridized to the Agilent bovine V1 4x44k DNA microarray. The comparison of untreated and treated bovine transcriptomes revealed a set of differentially expressed genes. After functional analysis and qPCR validation, 16 genes were found to be differentially expressed among groups (15 downregulated genes & 1 upregulated gene between CTR and DEX and CTR and DEX CLEN groups, respectively). A total of 24 animals was used in this study. Animals were randomly divided into three groups of 8 animals each. The first group was used as a control (CTRL), the second was treated with dexamethasone (DEX) administered via feed 0.75 mg per capita for 42 days (group DEX), and the third one was treated with an increasing dose of Clenbuterol (CLEN) via feed 2 mg per capita during the first week, 4 mg per capita during the second week, and 6 mg per capita during the third and the fourth weeks (28 days in total), in combination with DXM 0.66 mg per capita for 21 days (group DEX+ CLEN).Twelve samples (4/group) out of the 24 were chosen for the microarray analysis based on the highest isolated RNA quality.
2015-07-27 | E-GEOD-61934 | biostudies-arrayexpress
Project description:A bovine oligo microarray platform (GPL7053) was used to profile gene expression from twenty-five (25) bovine biceps brachii samples randomly collected at the slaughterhouse. Four (4) of these animals were suspected for corticosteroids treatment at tymus histological analyses. Eighteen (18) negative controls animals were also included. Analysis with PAM (Prediction Analysis of Microarray) identified ten (10) genes as potential biomarkers that best discriminated control animals from the animals suspected for corticosteroids treatment.
2012-12-20 | GSE26318 | GEO
Project description:A bovine oligo microarray platform (GPL7053) was used to evidence differences in gene expression profiles from thirty (30) muscle samples from growth promoters-treated cows and ten (10) from control animals. In this study, we analyzed forty (40) bovine biceps brachii samples, thirty (30) from growth promoters treated cows and ten (10) from control animals. Gene expression profiling was performed using the Agilent-015354 Bos taurus Oligo Microarray platform (GPL7053) based on single-colour detection (Cyanine-3 only). Microarrays were scanned with Agilent scanner G2565BA (barcode on the left, DNA on the back surface, scanned through the glass) at a resolution of 5 microns; all slides were scanned twice at two different sensitivity settings (XDRHi 100% and XDRLo 10%); the scanner software created a unique ID for each pair of XDR scans and saved it to both scan image files. Feature Extraction (FE) 9.5 used XDR ID to link the pairs of scans together automatically when extracting data. The signal left after all the FE processing steps have been completed is ProcessedSignal that contains the Multiplicatively Detrended, Background-Subtracted Signal.
2015-05-04 | E-GEOD-52779 | biostudies-arrayexpress
Project description:A bovine oligo microarray platform (GPL7053) was used to profile gene expression from twenty-five (25) bovine biceps brachii samples randomly collected at the slaughterhouse. Four (4) of these animals were suspected for corticosteroids treatment at tymus histological analyses. Eighteen (18) negative controls animals were also included. Analysis with PAM (Prediction Analysis of Microarray) identified ten (10) genes as potential biomarkers that best discriminated control animals from the animals suspected for corticosteroids treatment. In this study, we analyzed forty-three (43) bovine muscle samples, twenty-five (25) unknown samples and eighteen (18) negative controls. Gene expression profiling was performed using the Agilent-015354 Bos taurus Oligo Microarray platform (GPL7053) based on single-colour detection (Cyanine-3 only). Microarrays were scanned with Agilent scanner G2565BA (barcode on the left, DNA on the back surface, scanned through the glass) at a resolution of 5 microns; all slides were scanned twice at two different sensitivity settings (XDRHi 100% and XDRLo 10%); the scanner software created a unique ID for each pair of XDR scans and saved it to both scan image files. Feature Extraction (FE) 9.5 used XDR ID to link the pairs of scans together automatically when extracting data. The signal left after all the FE processing steps have been completed is ProcessedSignal that contains the Multiplicatively Detrended, Background-Subtracted Signal.
2012-12-20 | E-GEOD-26318 | biostudies-arrayexpress
Project description:In the present study, an attempt to compare bovine transcriptome of two different tissue matrices (liver and muscle) treated with the same molecules (trenbolone acetate (TBA) and estradiol (E2)) was carried out in order to understand the response of different tissues to the same treatment on a genomic/transcriptomic level. The primary aim of this study was to compare, via transcriptomic approach, the response of both muscle and liver to anabolic steroids, and to point out the main differences and similarities between both matrices. In addition, a second aim was to list out the main differentially expressed (DE) genes that can be used as a “pool” for biomarker investigations in the future. A bovine oligo microarray platform (GPL7053) was used to profile gene expression from thirty (30) bovine liver and muscle (biceps brachii) samples. Isolated and purified total RNAs were individually hybridized to the Agilent bovine V1 4x44k DNA microarray. The comparison of untreated and treated bovine transcriptomes revealed a set of differentially expressed genes. After functional analysis and qPCR validation, the result showed that the two transcriptomes showed completely different patterns, in terms of altered pathways and involved biological processes, following the treatment with anabolic steroids. However, they had 20 commonly expressed genes in-between.
2015-10-02 | GSE62002 | GEO
Project description:A bovine oligo microarray platform (GPL7053) was used to evidence differences in gene expression profiles from twenty-four (24) muscle samples from growth promoters-treated cows and thirteen (13) from control animals. Two-factor ANOVA was performed using age and treatment as independent categorical variables and 958, 2695 and 2482 genes were found significantly regulated by the treatment for Finaplix, Revalor and Revalor plus dexamethasone, respectively. In this study, we analyzed thirty-seven (37) bovine biceps brachii samples, twenty-four (24) from growth promoters treated cows and thirteen (13) from control animals. Gene expression profiling was performed using the Agilent-015354 Bos taurus Oligo Microarray platform (GPL7053) based on single-colour detection (Cyanine-3 only). Microarrays were scanned with Agilent scanner G2565BA (barcode on the left, DNA on the back surface, scanned through the glass) at a resolution of 5 microns; all slides were scanned twice at two different sensitivity settings (XDRHi 100% and XDRLo 10%); the scanner software created a unique ID for each pair of XDR scans and saved it to both scan image files. Feature Extraction (FE) 9.5 used XDR ID to link the pairs of scans together automatically when extracting data. The signal left after all the FE processing steps have been completed is ProcessedSignal that contains the Multiplicatively Detrended, Background-Subtracted Signal.
2014-08-28 | E-GEOD-47827 | biostudies-arrayexpress
Project description:Background Clenbuterol, a beta-agonist, can dramatically reduce pig adipose accumulation at high dosages. However, it has been banned in pig production because people who eat pig products treated with clenbuterol can be poisoned by the clenbuterol residues. To understand the molecular mechanism for this fat reduction, cDNA microarray, real-time PCR, two-dimensional electrophoresis and mass spectra were used to study the differential gene expression profiles of pig adipose tissues treated with/without clenbuterol. The objective of this research is to identify novel genes and physiological pathways that potentially facilitate clenbuterol induced reduction of adipose accumulation. Results Clenbuterol was found to improve the lean meat percentage about 10 percent (P< 0.5). The adipose cells became smaller and the muscle fibers became thicker with the administration of clenbuterol. The mRNA abundance of 82 genes (ESTs) were found to be statistically differentially expressed based on the Student t-test (P<0.5) in the microarray analyses which containing 3358 genes (ESTs).Theses 82 genes (ESTs) were divided into four groups according to their Gene Ontology Biological Process descriptions. 16 genes were cellular metabolism related genes (including five lipids metabolism related such as apolipoprotein D and apolipoprotein R), 10 were signal transduction related genes, 45 were expressed sequence tags (ESTs) and other 11 others were of various categories. Eleven of the 82 genes (ESTs) were chosen for real-time PCR analysis, with eight of them induced to express similar magnitudes as in the microarray analyses, two could not be detected and one expressed magnitudes that disagreed with the microarray results. Apolipoprotein R was also found to be up-regulated by the proteomic analysis. Conclusions Profound changes were observed in adipose cells after administration of clenbuterol in pigs by histological section and cDNA microarray techniques. The adipose cells became smaller with stimulation by clenbuterol. Changes in mRNA abundance indicated that DNA transcription and protein translation were enhanced in the adipose cells with clenbuterol stimulation. Five lipids metabolism related genes, such as apoD and apoR, were significantly up-regulated. ApoR was up-regulated in both the mRNA transcription and the protein synthesis. ApoR may be one of the critical molecules through which clenbuterol reduces fat accumulation. Keywords: dose response
2007-12-17 | GSE8093 | GEO
Project description:Clenbuterol-HCL can greatly reduce fat deposition and increase skeletal muscle growth at high dosages. In order to advance our understanding of the fundamental molecular mechanisms, Genechips were used to study the differential gene expression profiles of liver tissues among the pigs with/without Clenbuterol-HCL. Differentially expressed genes identified will be the candidates for further investigations on the molecular mechanisms involved in Clenbuterol-HCL of exerting repartition effects on adipose and skeletal muscle tissue.
2010-07-01 | GSE13786 | GEO
Project description:Background: Clenbuterol, a beta2-adrenergic receptor agonist, is used therapeutically to treat respiratory conditions in the horse. However, by virtue of its mechanism of action it has been suggested that clenbuterol may also have repartitioning affects in horses and as such the potential to affect performance. Clenbuterol decreases the percent fat and increases fat-free mass following high dose administration in combination with intense exercise in horses. In the current study, microarray analysis and real-time PCR were used to study the temporal effects of low and high dose chronic clenbuterol administration on differential gene expression of several skeletal muscle myosin heavy chains, genes involved in lipid metabolism and the β2-adrenergic receptor. The effect of clenbuterol administration on differential gene expression has not been previously reported in the horse, therefore the primary objective of the current study was to describe clenbuterol-induced temporal changes in gene expression following chronic oral administration of clenbuterol at both high and low doses. Steady state clenbuterol concentrations were achieved at approximately 50 hours post administration of the first dose for the low dose regimen and at approximately 18-19 days (10 days post administration of 3.2 μg/kg) for the escalating dosing regimen. Following chronic administration of the low dose (0.8 µg/kg BID) of clenbuterol, a total of 114 genes were differentially expressed, however, none of these changes were found to be significant following FDR adjustment of the p-values. A total of 7,093 genes were differentially expressed with 3,623 genes up regulated and 3,470 genes down regulated following chronic high dose administration. Of the genes selected for further study by real-time PCR, down-regulation of genes encoding myosin heavy chains 2 and 7, steroyl CoA desaturase and the β2-adrenergic receptor were noted. For most genes, expression levels returned towards baseline levels following cessation of drug administration. Conclusion: This study showed no evidence of modified gene expression following chronic low dose administration of clenbuterol to horses. However, following chronic administration of high doses of clenbuterol alterations were noted in transcripts encoding various myosin heavy chains, lipid metabolizing enzymes and the β2-adrenergic receptor.
2016-03-24 | GSE79559 | GEO
Project description:Myotonic Dystrophy Type-2 (DM2) is an autosomal dominant disease caused by the expansion of a CCTG tetraplet repeat. It is a multisystemic disorder, affecting skeletal muscles, the heart, the eye, the central nervous system and the endocrine system. Whole mRNAs expression was measured in the muscle of DM2 patients and compared it to controls.We identified distinct genes modulated in DM2 patients compared to controls. Our study included 10 DM2 and 10 control (CTR) muscle biopsies from biceps brachii. DM2 and CTR were age- and sex- matched. Most DM2 patients had myotonia and cataract, two disease hallmarks, while differences in other clinical parameters (muscle strenght, diabetes, CPK, FT3, FT4, TSH, ejection fraction) were not significant. Genes expression was assessed by Affymetrix Gene Chip Human Exon 1.0 ST Array.
2015-04-05 | E-GEOD-37084 | biostudies-arrayexpress